RECENT NEWS

July 1, 2019

Synergys announces second Phase 1 SBIR funding from NIH for development of vasculogenic mimicry-blocking antibody fusion product for ovarian cancer.

October 17-18, 2017

Dr. Rathin Das, CEO, Synergys, gave a presentation at the BIO Investor Forum in San Francisco, CA.

 

September 26, 2017

SYNERGYS Announces Phase 1 SBIR Grant Award From National Institutes of Health. Grant from NIH's National Cancer Institute will support development of Vasculogenic Mimicry-blocking Antibody Fusion products for Triple Negative Breast Cancer.

 

October 2, 2015

Dr. Rathin Das., CEO, Synergys, spoke at the LakePharma Protein Engineering Symposium on A-TAP fusion protein for cancer treatment.

 

June 30, 2015

Dr. Rathin Das, CEO, Synergys, discussed the status of the development of A-TAP product candidates at the Bio2Device group meeting at San Jose, CA.

 

November 10, 2014

Prof. Mark Pegram, MD, Director of the Breast Cancer Treatment Program of Stanford University Cancer Institute, Palo Alto, CA, joined Synergys' Scientific Advisory Board.

 

April 24, 2013
Established research collaboration with a major US university on the preclinical development of Anti-Ang-1/2 MAb program.

April 18, 2013
Biologics World Korea, Seoul, Korea
Dr. Elizabeth Song, Advisor, presented the status of the Company’s Anti-Ang-1/2 MAb program at the conference.

December 6, 2012
IBC Antibody Engineering and Antibody Therapeutics Conferences, San Diego, CA
In its 23rd year, Antibody Engineering and Antibody Therapeutics is the world's largest forum to discuss up-to-date status of antibody engineering and therapeutics development.

 

Dr. Rathin Das, CEO chaired a session in the Antibody Therapeutics forum and Dr. Steve Carroll, Head of R & D, gave an invited presentation on the development status of the Company’s Anti-Ang-1/2 MAb program.

October 30, 2012
BayBio, Northern California’s life science association

Provided Synergys a one year membership into its Fellows program.

May 11 , 2012
Synergys initiated a collaboration with a US company to generate mammalian cell-based production of its ATEP-based product candidate.

March 7, 2011 
Synergys entered into a licensing and option agreement with a US university for in-licensing of anti-angiogenesis agent.

January 3, 2011
Synergys entered into a licensing and option agreement with a South Korean pharma company for in-licensing of anti-cancer agent.


PUBLICATION



February 1, 2013

Biopharm International
Published an article titled “Therapeutic Antibodies in Review”, co-authored by Rathin Das, CEO



March 10, 2011

A publication in Molecular Cancer Therapeutics,  2011;10:603-614, titled "Targeted Delivery of an Antibody-Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy" by Seung-Uon Shin, Hyun-Mi Cho, Jaime Merchan, Jin Zhang, Krisztina Kovacs,Yawu Jing, Sundaram Ramakrishnan, and Joseph D. Rosenblatt.



Medicine, the only profession that labors incessantly to destroy the reason for its existence.
                                           
-James Bryce